Kuwait University

Milad S Bitar

Fahd Al-Mulla

Jean Paul Thiery

A method of healing a wound in a patient, can include administering to a patient in need thereof a therapeutically effective amount of Sulforaphane-Cysteine (SFN-Cys). The therapeutically effective amount may be 1.5 μM. The SFN-Cys may be combined with an excipient and the excipient may be a poloxamer. The SFN-Cys, combined with a poloxamer, may be applied topically or taken orally.

Sulforaphane-cysteine for wound healing in diabetic subjects

The method of treating delayed healing of a wound associated with diabetes includes administering to the wound a composition comprising an anti-senescence compound and a pharmaceutically acceptable carrier. The anti-senescence compound may be 18&#x3b1;-Glycyrrhetinic acid, a Caveolin-1 (Cav-1) inhibitory compound, or a Polymerase I Transcript Release Factor (PTRF-1) inhibitory compound. The anti-senescence compound may be effective in preventing and/or reversing premature cellular senescence. The anti-senescence compound may be effective in promoting healing of a wound, e.g., delayed or incompletely healed wound. The anti-senescence compound may be effective in promoting healing of a delayed healing wound or chronic wound of a diabetic patient, such as a diabetic ulcer or venous ulcer.

Method of treating delayed healing of a wound associated with diabetes

The method for determining risk of metastatic relapse in a patient diagnosed with colorectal cancer (CRC) can include detecting a level of at least one indicator of metastatic potential in a biological sample from the patient, comparing the level of the indicator of metastatic potential with a control, and identifying the patient as one who is at risk of metastatic relapse and a candidate for chemotherapy if an aberrant level of the indicator of metastatic potential in the biological sample compared to the control is detected. The at least one indicator of metastatic potential can include at least one metastasis-inducing gene and/or at least one metastasis suppressor gene. An aberrant level of the at least one indicator of metastatic potential can include a copy number gain of the metastasis-inducing gene and/or a copy number loss of the metastasis-suppressor gene.

Method for determining risk of metastatic relapse in a patient diagnosed with colorectal cancer

The method of treating diabetes-related impaired wound healing includes the step of administering an effective amount of estrogen replacement therapy to a patient in need thereof to promote wound healing. Alternatively, the method of treating diabetes-related impaired wound healing includes the step of administering an effective amount of a TNF-&#x3b1; inhibitor to a patient in need thereof to promote wound healing. The method of treating diabetes-related impaired wound healing may also include both the step of administering an effective amount of estrogen replacement therapy and administering an effective amount of a TNF-&#x3b1; inhibitor to a patient in need thereof to promote wound healing.

Method of treating diabetes-related impaired wound healing

The method of treating diabetes-related vascular complications includes the treatment of diabetic patients with &#x3b1;-lipoic acid (LA) in order to mitigate the negative impact of diabetes-related vascular dysfunctions upon vascular homeostasis. The treatment method includes the step of administering to the patient an initial dosage of &#x3b1;-lipoic acid believed to be therapeutically effective. The patient's response is then monitored by measuring &#x3b1;-lipoic acid-responsive biomarkers and by performing assays from blood and tissue taken from the patient.

Method of treating diabetes-related vascular complications

The method of diagnosing and treating oxidative stress-impaired wound healing allows a practitioner to identify a subject at risk of having impaired wound healing by identifying the sensitivity of that patient to IGF-1. A finding of IGF-1 resistance, either systemically or at the site of an already existing wound, indicates an increased likelihood that the wound will have difficulty healing. In addition, identifying IGF-1 resistance by this method indicates that treatment of a wound with a combination of an antioxidant, IGF-1 and IGFBP-1 will provide optimal healing.

Growing community of inventors

Salmiya, Kuwait

Milad S Bitar